Rite Aid front-end comps up 3.8% amid shift in timing of Easter

Retail pharmacy chain reports 0.3% increase in same-store prescription count

CAMP HILL, Pa. — Same-store sales at Rite Aid decreased 2% in March, including a 3.8% increase in same-store sales on the front end and a 4.5% decrease in pharmacy sales due in part to new introductions of generic drugs, the retail pharmacy chain said Thursday.

The 4,621-store chain reported total sales for the month of $1.939 billion, a 2.5% decrease compared with $1.989 billion in March 2012, while same-store prescription count increased 0.3%.

The company said that of the 3.8% increase in front-end same-store sales, 3% came from a shift in timing of Easter, which fell on March 31, as opposed to April 8 last year.

Investment firm Guggenheim Partners maintained its "Buy" rating on Rite Aid's stock, saying it expected the company to post strong and above-trend growth in EBITDA in its fourth quarter 2012 earnings, which it will report next Thursday. Guggenheim analyst John Heinbockel noted that script count was below the 1.5% recent trendline, and the reason was unclear but appeared to be due to a weakening of the economy, but the firm expects the meaningful generic drug benefit to GM to persist into the first quarter of fiscal year 2014. 

Recommended stories

Login or Register to post a comment.